Compare GSK plc (GSK) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JPMorgan Chase & Co — how do they compare? GSK plc trades at $52.81 (market cap $101.34B), while JPMorgan Chase & Co trades at $343.52 (market cap $922.16B). The key difference: JPMorgan Chase & Co is far larger — about 9.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | JPM | |
|---|---|---|
Market Cap | $101.34B | $922.16B |
Sector | Health | Financials |
52-Week High | $61.18 | $346.91 |
52-Week Low | $36.20 | $282.84 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 1.73% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
JPMorgan Chase (JPM) trades at $345.27, up 0.69% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $7.59, beating expectations of $5.59, and revenue growth to $181.85B in 2025. Analyst consensus is a Moderate Buy with a $372 price target, and institutional buying activity remains positive amid macroeconomic optimism.
The outlook for JPM is positive, supported by earnings momentum and sector resilience, but risks include geopolitical tensions, cybersecurity threats, and interest rate sensitivity. The stock offers potential upside to the consensus target, though investors should monitor cost pressures and economic volatility highlighted in recent CEO commentary.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
